Fuzionaire Theranostics

The Woodlands, United States Founded: 2018 • Age: 8 yrs
Develops theranostics platform for cancer diagnostics and therapies via innovative chemistry.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors - Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Fuzionaire Theranostics

Fuzionaire Theranostics is a company based in The Woodlands (United States) founded in 2018. It operates as a B2B. Fuzionaire Theranostics offers products and services including HetSiFA Platform and GRPR Theranostic Pair. Fuzionaire Theranostics operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Ariceum Therapeutics, among others.

  • Headquarter The Woodlands, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Fuzionaire Theranostics

Fuzionaire Theranostics offers a comprehensive portfolio of products and services, including HetSiFA Platform and GRPR Theranostic Pair.

Product name locked
Category locked
Primary

Enables creation of personalized cancer diagnostics and therapies.

Product name locked
Category locked
Locked

Targets prostate cancer receptors for diagnostic and treatment purposes.

Funding Insights of Fuzionaire Theranostics

Premium access

Detailed funding history for Fuzionaire Theranostics

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Fuzionaire Theranostics

Investments
Premium access

Investment portfolio details for Fuzionaire Theranostics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Fuzionaire Theranostics

Premium access

Detailed financials for Fuzionaire Theranostics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Fuzionaire Theranostics Comparisons

Fuzionaire Theranostics Primary company
Description
Develops theranostics platform for cancer diagnostics and th...
Location
The Woodlands, United States
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Fuzionaire Theranostics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Fuzionaire Theranostics

Fuzionaire Theranostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, Mariana Oncology, AdvanCell and Ariceum Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
Locked Locked Locked
Developer of molecular imaging systems and radio-pharmaceuticals
Locked Locked Locked
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
Locked Locked Locked
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
Locked Locked Locked
Developer of drugs for systemic targeted radiation therapy to treat cancer
Locked Locked Locked
Developer of diagnostic imaging agents and targeted therapeutics
Premium access

Detailed competitors of Fuzionaire Theranostics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Fuzionaire Theranostics

Premium access

Complete news archive for Fuzionaire Theranostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fuzionaire Theranostics

Fuzionaire Theranostics was founded in 2018.

Fuzionaire Theranostics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.

Fuzionaire Theranostics focuses on creating radiopharmaceuticals for theranostics, combining PET diagnostics and radioligand therapies. Using the HetSiFA platform derived from breakthroughs at Caltech, they produce chemically identical diagnostic and therapeutic agents. This enables personalized cancer care by targeting specific receptors, such as in prostate cancer. Based in the USA, they collaborate with institutions to scale treatments and address oncology needs, improving accessibility for patients.

Fuzionaire Theranostics's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.

Fuzionaire Theranostics offers HetSiFA Platform and GRPR Theranostic Pair.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available